NSAIDs and Prostate Cancer Risk
Author Information
Author(s): Mahmud Salaheddin M., Franco Eduardo L., Turner Donna, Platt Robert W., Beck Patricia, Skarsgard David, Tonita Jon, Aprikian Armen G.
Primary Institution: McGill University
Hypothesis
Do non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of prostate cancer?
Conclusion
The study suggests that using certain NSAIDs, particularly propionates, may modestly reduce the risk of prostate cancer.
Supporting Evidence
- Any use of propionates was associated with a modest reduction in prostate cancer risk.
- Aspirin use did not show a significant inverse association with prostate cancer risk.
- Most cases were older than 65 years at diagnosis.
Takeaway
Taking some pain relievers called NSAIDs might help lower the chances of getting prostate cancer, but not all types work the same way.
Methodology
A nested case-control study using data from Saskatchewan Prescription Drug Plan and Cancer Registry to analyze NSAID use and prostate cancer risk.
Potential Biases
Potential for differential misclassification due to screening practices among NSAID users.
Limitations
The study lacked information on over-the-counter NSAID use and PSA testing, which could affect the results.
Participant Demographics
Men aged 40 years or older diagnosed with prostate cancer between 1985 and 2000.
Statistical Information
P-Value
p<0.001
Confidence Interval
95%CI 0.84-0.95
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website